Europe — EMA
Nebivolol Zentiva
GNH USA supplies Nebivolol Zentiva (Nebivolol), a β1‑selective beta‑blocker for hypertension and heart failure. Request a quote for global supply.
Request sourcing
What is Nebivolol?
Nebivolol, the active ingredient in Nebivolol Zentiva, is a β1‑selective beta‑blocker presented as an oral tablet for oral use. It is used to lower elevated blood pressure and may be prescribed for patients with hypertension or certain forms of heart failure.
GNH USA supplies Nebivolol Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.
What is Nebivolol used for?
Nebivolol is a β1‑selective beta‑blocker indicated for cardiovascular conditions that involve elevated blood pressure.
Hypertension: reduces systolic and diastolic blood pressure, improving overall cardiovascular risk profile. Heart failure: enhances left ventricular function and alleviates symptoms in patients with chronic heart failure.
What are the side effects of Nebivolol?
Nebivolol may cause a range of adverse reactions, which are categorized by frequency and severity.
Common Side Effects: - Headache - Dizziness - Fatigue
Serious or Rare Side Effects: - Severe bradycardia - Symptomatic hypotension - Bronchospasm
What precautions apply to Nebivolol?
Before initiating therapy, clinicians should consider several safety measures.
Monitor blood pressure: ensure adequate control without excessive lowering. Assess cardiac function: evaluate baseline heart rate and rhythm. Use caution in asthma or COPD: β1‑selectivity may still affect bronchial tone. Adjust dose in renal/hepatic impairment: reduced clearance may increase exposure. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Store at room temperature: keep in the original pack, protect from moisture.
What does Nebivolol interact with?
Nebivolol can interact with other medicines, requiring attention to avoid adverse outcomes.
Major Interactions (Avoid): - Concomitant use with other beta‑blockers - Co‑administration with non‑dihydropyridine calcium channel blockers (verapamil, diltiazem) - Use with clonidine or abrupt withdrawal of clonidine
Moderate Interactions (Monitor Closely): - Combined therapy with insulin or oral hypoglycemics (may mask hypoglycemia) - NSAIDs may diminish antihypertensive effect - Other antihypertensives (ACE inhibitors, ARBs) may enhance blood‑pressure lowering - Certain antidepressants (SSRIs) can increase bradycardia risk
